Table 2. Patient baseline demographic and clinical characteristics.
| Characteristic | Formulation 1 (N=43) | Formulation 2 (N=34) |
|---|---|---|
| Median (range) age, years | 52.7 (23.5–69.9) | 56.0 (23.4–73.2) |
| Gender, n (%) | ||
| Male | 27 (62.8) | 24 (70.6) |
| Female | 16 (37.2) | 10 (29.4) |
| Tumor type, n (%) | ||
| Colorectal carcinoma | 9 (20.9) | 0 |
| Hepatocellular carcinoma | 8 (18.6) | 9 (26.5) |
| Stromal tumor | 8 (18.6) | 1 (2.9) |
| NET (grade 1/2)a | 7 (16.3) | 21 (61.8) |
| Non-small cell lung cancer | 2 (4.7) | 0 |
| Renal cell carcinoma | 2 (4.7) | 0 |
| Other | 7 (16.3) | 3 (8.8) |
| ECOG performance status, n (%) | ||
| 0 | 10 (23.3) | 4 (11.8) |
| 1 | 29 (67.4) | 30 (88.2) |
| 2 | 4 (9.3) | 0 |
| Median (range) time since diagnosis, years | 1.9 (0.1–11.2) | 0.8 (0.0–6.8) |
| Previous anti-tumor systemic therapy, n (%) | ||
| Yes | 33 (76.7) | 20 (58.8) |
| No | 10 (23.3) | 14 (41.2) |
aNET pathology grading was categorized according to Ki67 index and tumor cell mitotic rate. Grade 1 and 2 tumors were also reported as well-differentiated NETs.